Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.39 |
| ▸ | PPARA | Q07869 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | PPARD | Q03181 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PTPRF | P10586 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863184 | 0.97 | MAPT (0.38) | PPARGPPARAMAPTGAAALDH1A1 | |
| SCHEMBL14194982 | 0.97 | MAPT (0.38) | PPARGPPARAMAPTGAAALDH1A1 | |
| SCHEMBL1870590 | 0.94 | PPARG (0.39) | PPARGPPARAMAPTPPARDGAA | |
| SCHEMBL4825231 | 0.94 | PPARG (0.39) | PPARGPPARAMAPTPPARDGAA | |
| SCHEMBL4825018 | 0.93 | PPARG (0.39) | PPARGPPARAMAPTPPARDGAA | |
| SCHEMBL1860645 | 0.92 | PPARG (0.46) | PPARGPPARAPPARDPTPRFPTPN2 | |
| SCHEMBL1855249 | 0.91 | MAPT (0.35) | PPARGPPARAMAPTPPARDLMNA | |
| SCHEMBL1865976 | 0.90 | PPARG (0.41) | PPARGPPARAMAPTGAAALDH1A1 | |
| SCHEMBL1865594 | 0.90 | PPARG (0.38) | PPARGPPARAMAPTPPARDTP53 | |
| SCHEMBL4822987 | 0.89 | PPARG (0.49) | PPARGPPARAPPARDPTPRFPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105748-A1 | Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds | REDDY'S LABORATORIES INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105748-A1 | Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds | PCCA, ADRA1B, ADRA2B | PPARG 994/4885PPARA 822/4885MAPT 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.